Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)

Fig. 6

Overall survival according to sidedness and TP53 mutation status in first-line anti-EGFR treated metastatic colorectal cancer. Kaplan-Meier curves for overall survival in right-sided/TP53 mutant, right-sided/TP53. wild-type, left-sided/TP53 mutant and left-sided/TP53 wild-type metastatic colorectal cancer

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us